Safety concerns with J&J's COVID-19 vaccine present a big opportunity for Pfizer, Moderna: analyst

Developing a single-shot COVID-19 vaccine with less stringent cold-storage requirements seemingly gave Johnson & Johnson a major advantage over mRNA coronavirus vaccine producers. As a result, its rollout was anxiously awaited. But with a pause of the J&J shot in the United States and Europe as officials investigate rare and severe blood clots, that edge is quickly diminishing. The advantage, now, goes to Moderna and Pfizer-BioNTech, a biopharma analyst writes.
Read more...

;